UNSPSC 51122806: Guafecainol

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L68QKU1H9U. European Medicines Agency schedules Guafecainol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07969MIG. Guafecainol generally arises in the molecular formula C16H27NO4.

UNSPSC 51122806 Guafecainol, a Commodity code, encompasses pharmaceutical supply to state and local government agencies and special districts, with recent solicitations focused on emergency medical services, pharmacy benefit programs, and cooperative purchasing arrangements for generic and branded medications. State and local governments procure medications under this code primarily through sealed-bid processes, Request for Information (RFI) mechanisms, and cooperative purchasing vehicles, with issuing bodies spanning city fire departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves sourcing specific pharmaceutical products with defined National Drug Codes (NDCs), meeting FDA compliance and Good Manufacturing Practices (cGMP) standards, managing expiration dates and shelf-life requirements, maintaining chain-of-custody documentation, and coordinating with authorized wholesalers or direct-to-manufacturer channels.

Recent activity shows geographic spread across Florida, Texas, and Minnesota-led multistate arrangements. The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with a response deadline of April 8, 2026 and estimated contract value of $40,000.00, incorporating a 5 percent Small Local Business Enterprise sheltered-market discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (due April 3, 2026) to assess vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state intent to explore alternative supply-chain models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with an effective date of July 1, 2026 and contract duration of two years plus optional extensions.